PRT811 Trials

Proven success in rapidly advancing novel therapeutics to clinical trials for cancer patients.

Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of Oral PRT811 in Subjects with Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas– PRT811-01 (NCT04089449)


Oral PRT811

Trial Status:

Actively Recruiting

Trial Information:

PRT811 is designed to be an oral, potent, and selective brain penetrant Protein Arginine Methyl Transferase 5 (PRMT5) inhibitor. PRMT5 is believed to mediate cancer progression in tumors, including central nervous system (CNS) lymphomas and glioblastoma multiforme (GBM).

This Phase 1 dose-escalation/dose-expansion study will seek to define a safe dose and schedule to be used in subsequent development of PRT811. The study will enroll patients with certain advanced solid tumors who have exhausted available treatment options, including:

  • Glioblastoma multiforme (GBM)
  • Primary central nervous system lymphomas (PCNSL)
  • Homologous recombination deficient positive (HRD+) tumors with brain metastases

For full trial information, please visit or contact us directly at [email protected].